RAINBOW - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.7
| Stock Code | RAINBOW | Market Cap | 12,718 Cr. | Current Price | 1,252 ₹ | High / Low | 1,646 ₹ |
| Stock P/E | 51.9 | Book Value | 156 ₹ | Dividend Yield | 0.24 % | ROCE | 18.3 % |
| ROE | 16.7 % | Face Value | 10.0 ₹ | DMA 50 | 1,222 ₹ | DMA 200 | 1,293 ₹ |
| Chg in FII Hold | -2.00 % | Chg in DII Hold | 1.63 % | PAT Qtr | 65.8 Cr. | PAT Prev Qtr | 73.2 Cr. |
| RSI | 54.5 | MACD | 18.9 | Volume | 72,911 | Avg Vol 1Wk | 1,01,882 |
| Low price | 1,009 ₹ | High price | 1,646 ₹ | PEG Ratio | 2.91 | Debt to equity | 0.46 |
| 52w Index | 38.2 % | Qtr Profit Var | -1.73 % | EPS | 24.2 ₹ | Industry PE | 47.1 |
📈 Optimal Buy Price: 1,245–1,260 ₹
🎯 Profit-Taking Levels: 1,290–1,310 ₹
🛡️ Stop-Loss / Exit Zone: 1,230 ₹
⏳ Intraday Exit Guidance:
- Exit if price fails to sustain above 1,245 ₹ with weakening volume.
- Book profits near 1,290–1,310 ₹ if RSI approaches 58–60 and momentum slows.
- Intraday exit if MACD momentum fades or RSI dips below 52 with declining participation.
---
Positive
- Strong ROCE (18.3%) and ROE (16.7%) indicate efficient capital use.
- EPS at 24.2 ₹ supports earnings base.
- Trading above 50 DMA (1,222 ₹), showing near-term support.
- DII inflows (+1.63%) show domestic investor confidence.
- MACD positive (18.9) indicates short-term bullish bias.
Limitation
- RSI at 54.5 indicates neutral momentum.
- Price below 200 DMA (1,293 ₹), showing medium-term weakness.
- High P/E (51.9) compared to industry average (47.1).
- Quarterly PAT declined (65.8 Cr. vs 73.2 Cr., -1.73%).
- FII holdings reduced (-2.00%).
Company Negative News
- Profit contraction raises sustainability concerns.
- Foreign investor sentiment weakening.
Company Positive News
- Domestic institutional inflows support stability.
- Technical momentum supported by MACD and near-DMA strength.
- Strong liquidity ensures intraday trade viability.
Industry
- Industry PE at 47.1, slightly lower than company’s valuation.
- Healthcare sector supported by rising demand and premium services.
- Competitive landscape with moderate growth outlook.
Conclusion
RAINBOW is a moderate intraday candidate with valuation support and technical strength, but weak medium-term trend and declining profits limit upside. Tactical trades are viable with strict stop-loss near 1,230 ₹ and profit exits around 1,290–1,310 ₹. Existing holders should monitor RSI and MACD closely for intraday exit signals.
Would you like me to extend this into a sector overlay vs. Apollo Hospitals and Narayana Hrudayalaya, so you can benchmark RAINBOW’s intraday setup against other healthcare peers?